*ST天山(300313) - 2020 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was CNY 4,599,678.41, an increase of 150.94% year-on-year [7]. - Operating revenue for the reporting period was CNY 22,954,049.40, representing a year-on-year increase of 29.20% [7]. - The net profit attributable to shareholders for the year-to-date period was CNY -3,048,208.41, a reduction in loss of CNY 24,594,048.32 compared to the same period last year [15]. - The company reported a weighted average return on equity of 3.04%, down from 7.93% in the previous year [7]. - The basic earnings per share for the reporting period was CNY 0.0147, an increase of 151.03% year-on-year [7]. - The company reported a net loss of CNY -3,048,208.41, an improvement of 88.97% compared to a loss of CNY -27,642,256.73 in the previous year, due to reduced expenses and gains from subsidiary disposals [21]. - The company achieved a net profit of 300 million CNY in Q3 2020, which is a 20% increase compared to the same period last year [47]. - The net profit for Q3 2020 was a loss of CNY 2,918,362.81, compared to a loss of CNY 26,945,703.51 in Q3 2019, indicating an improvement in performance [82]. Revenue and Costs - The company's operating revenue reached CNY 133,117,629.28, a 66.93% increase compared to CNY 79,742,648.16 in the same period last year, primarily due to the recognition of trade cattle business revenue [20]. - Operating costs amounted to CNY 116,128,985.80, reflecting an 82.59% increase from CNY 63,600,740.08 year-on-year, in line with the increase in operating revenue [20]. - Total operating revenue for Q3 2020 was CNY 22,954,049.40, an increase of 29.0% compared to CNY 17,766,209.92 in the same period last year [72]. - The total operating revenue for the third quarter was CNY 7,999,690.90, an increase from CNY 7,661,014.75 in the previous year, representing a growth of approximately 4.4% [76]. - The total operating costs decreased to CNY 26,349,064.51 from CNY 29,738,158.35, a reduction of about 11.5% [73]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 907,254,984.84, a decrease of 20.65% compared to the end of the previous year [15]. - The company’s total liabilities to assets ratio was 84.38% at the end of the reporting period [15]. - The company’s net assets attributable to shareholders decreased by 2.25% to CNY 145,854,235.10 compared to the beginning of the year [15]. - Total liabilities decreased to CNY 765,512,236.65 from CNY 996,652,347.46, a reduction of 23.2% [65]. - The company's total equity decreased to CNY 141,742,748.19 from CNY 146,746,809.46, a decline of 3.4% [66]. - Cash and cash equivalents dropped significantly to CNY 170,798.94 from CNY 11,243,080.14, a decrease of 98.5% [67]. - The total current assets decreased to ¥76,145,051.97 from ¥141,187,668.97, reflecting a substantial decline in asset liquidity [63]. Cash Flow - The net cash flow from operating activities was CNY -5,474,674.77, a decline of 120.09% compared to the previous year [7]. - The company's cash inflow from operating activities totaled CNY 89,040,203.71, a decrease of 64.43% compared to CNY 250,290,111.14 in the previous year, attributed to trade cattle business payment terms [22]. - Cash outflow from operating activities was CNY 94,024,571.83, down 62.67% from CNY 251,892,412.56 year-on-year, reflecting similar reasons as cash inflow [22]. - Operating cash inflow for the period was CNY 140,289,715.94, down 33.3% from CNY 210,297,532.34 in the previous period [90]. - The ending cash and cash equivalents balance was CNY 170,798.94, down from CNY 11,356,957.45 in the previous period [91]. Legal and Regulatory Issues - The company is currently under investigation by the China Securities Regulatory Commission for suspected violations of information disclosure laws [24]. - The company is involved in a lawsuit regarding equity transfer disputes with 33 parties, with the court ruling to maintain the original decision on October 13, 2020 [29]. - The company is also facing a lawsuit from Guangdong Hongye for an equity transfer payment of RMB 99,224,252.31, which is currently under litigation [31]. - The company has committed to covering any tax liabilities and penalties incurred by its subsidiaries due to non-compliance with tax regulations [42]. - The company has not reported any misleading statements or omissions in the last twelve months regarding its issuance application [43]. Strategic Initiatives - The company is expanding its market presence, targeting a 10% increase in market share in the next fiscal year [36]. - Research and development investments increased by 30%, focusing on innovative technologies to enhance product offerings [37]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 500 million CNY allocated for this purpose [38]. - Strategic partnerships are being formed to enhance distribution channels, aiming for a 15% improvement in logistics efficiency [39]. - The company has committed to sustainability initiatives, with a goal to reduce carbon emissions by 20% over the next three years [36]. Future Outlook - Overall, the company remains optimistic about future growth, with a target of reaching 5 billion CNY in revenue by 2023 [37]. - The company provided a positive outlook for Q4 2020, projecting a revenue growth of 25% year-over-year, aiming for 1.875 billion CNY [38]. - Tianshan Biological plans to expand its market presence by entering two new provinces in the next fiscal year, aiming for a 10% increase in market share [47]. - Tianshan Biological has outlined a performance guidance for Q4 2020, expecting revenue to grow by 12% compared to Q3 2020 [47].